<SEC-DOCUMENT>0001193125-21-069471.txt : 20210304
<SEC-HEADER>0001193125-21-069471.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304160603
ACCESSION NUMBER:		0001193125-21-069471
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210303
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		21714158

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d146113d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;3, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>VIRACTA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-51531</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-3295878</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2533 S Coast Hwy 101, Suite 210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cardiff, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92007</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)
<FONT STYLE="white-space:nowrap">400-8470</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>VIRX</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2021, the Board of Directors (the &#147;Board&#148;) of Viracta Therapeutics, Inc. (the &#147;Company&#148;) increased the size of the Board
to nine (9)&nbsp;and appointed Barry J. Simon, M.D. and Stephen Rubino, Ph.D., MBA to the Board to fill the vacancies resulting from such increase, in each case effective March&nbsp;3, 2021. Dr.&nbsp;Simon will serve as a Class&nbsp;II director and
Dr.&nbsp;Rubino will serve as a Class&nbsp;III director. In addition, as set forth below, Dr.&nbsp;Simon was appointed as the Chairperson of the Compensation Committee and a member of the Audit Committee and Dr.&nbsp;Rubino was appointed as a member
of the Audit Committee and the newly formed Science and Technology Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Simon, 56, has served the President and Chief Administrative
Officer of NantKwest, Inc. since January&nbsp;2017 and served as President and Chief Operating Officer from March&nbsp;2015 to December&nbsp;2016. From 2007 to March&nbsp;2015, Dr.&nbsp;Simon was NantKwest&#146;s President and Chief Executive
Officer. Dr.&nbsp;Simon has also served on the Board of Directors of NantKwest since 2007. He also serves on the board of directors of Cue BioPharma, a biopharmaceutical company and Brink Biologics Inc., a bioanalytics, reagents and testing services
company, and previously served on the board of directors of Viracta Subsidiary, Inc. (previously named Viracta Therapeutics, Inc.) from July 2017 to November 2020. Previously, Dr.&nbsp;Simon held Vice President, senior level and advisory positions <FONT
STYLE="white-space:nowrap">at&nbsp;F.&nbsp;Hoffmann-La&nbsp;Roche,&nbsp;a</FONT> global healthcare company, Roche Labs, a pharmaceuticals company, Connetics Corporation, a specialty pharmaceutical company, Immunomedics, a biopharmaceutical company,
Immusol, a biopharmaceutical company, HealthPro BioVentures,&nbsp;LLC, a healthcare and life sciences investment bank and NorthSound Capital,&nbsp;LLC, a U.S.-based hedge fund. Dr.&nbsp;Simon attended corporate training programs by the London School
of Business and the Amos Tuck School of Business at Dartmouth College. Dr.&nbsp;Simon trained clinically in Infectious Diseases at Albert Einstein College of Medicine, Anesthesiology at The Mount Sinai Medical Center and Internal Medicine at New
York University and received his M.D. from the SUNY Downstate Health Sciences Center in New York. The Board believes that Dr.&nbsp;Simon is qualified to serve as a member of the Board because of his extensive medical and scientific knowledge and
experience, as well as his senior management experience in the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Rubino, 62, has served as the Chief Business Officer
of Celyad Oncology, a biotechnology company, since February 2020. Previously, Dr.&nbsp;Rubino served as Chief Business and Strategy Officer at Omega Therapeutics from May 2018 to May 2019, as an Entrepreneur in Residence at Fortress Biotech from
March 2017 to May 2018, and in various positions at Novartis, a biotechnology company, from 2001 until 2017, including most recently as Global Head of Business Development&nbsp;&amp; Licensing and New Product Marketing, Cell&nbsp;&amp; Gene Therapy
Unit, from November 2014 to March 2017. Dr.&nbsp;Rubino also serves on the board of directors of Sermonix Pharmaceuticals. Dr.&nbsp;Rubino received a Ph.D. in virology from Cornell University and an M.B.A. from Baruch College. The Board believes
Dr.&nbsp;Rubino is qualified to serve on the Board because of his extensive management and commercial experience in the fields of biotechnology and oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Dr.&nbsp;Simon and Dr.&nbsp;Rubino will be compensated in accordance with the Company&#146;s amended and restated outside director compensation
policy, which has been filed as Exhibit 10.2 to the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;8, 2017. In addition, each of Dr.&nbsp;Simon and Dr.&nbsp;Rubino will enter into
the Company&#146;s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.5 to the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-121646)</FONT> filed with the SEC on December&nbsp;23, 2004. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding
between either Dr.&nbsp;Simon or Dr.&nbsp;Rubino and any other persons pursuant to which either Dr.&nbsp;Simon or Dr.&nbsp;Rubino was elected as a director.&nbsp;In addition, neither Dr.&nbsp;Simon nor Dr.&nbsp;Rubino is a party to any transaction,
or series of transactions, required to be disclosed pursuant to Item&nbsp;404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.&nbsp;There</FONT> are no family relationships between either of Dr.&nbsp;Simon or Dr.&nbsp;Rubino and any of the
Company&#146;s directors or executive officers. The Board has determined that Dr.&nbsp;Simon and Dr.&nbsp;Rubino meet the applicable independence requirements of The Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Promotion of Chief Operating Officer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on
March&nbsp;3, 2021, the Board approved the promotion of Daniel Chevallard, the Company&#146;s Chief Financial Officer, Treasurer and Secretary to the additional role of Chief Operating Officer. There were no changes to Mr.&nbsp;Chevallard&#146;s
compensation arrangements in connection with the promotion. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Board Committees </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointments of Dr.&nbsp;Simon and Dr.&nbsp;Rubino to the Board, the Board approved the reconfiguration of the Board committees as
follows, in each case effective as of March&nbsp;3, 2021: (i) Thomas E. Darcy, Dr.&nbsp;Rubino and Dr.&nbsp;Simon were appointed to the Audit Committee of the Board, and Mr.&nbsp;Darcy was appointed as the Chairperson of the Audit Committee,
(ii)&nbsp;Dr.&nbsp;Simon, Mr.&nbsp;Darcy and Michael Huang, M.S., M.B.A. were appointed to the Compensation Committee of the Board, and Dr.&nbsp;Simon was appointed as the Chairperson of the Compensation Committee, and (iii)&nbsp;Roger J. Pomerantz,
M.D., Nicole Onetto, M.D. and Gur Roshwalb, M.D., were appointed to the Nominating and Corporate Governance Committee of the Board, and Dr.&nbsp;Pomerantz was appointed as the Chairperson of the Nominating and Corporate Governance Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, also on March&nbsp;3, 2021, the Board approved the formation of a new Science and Technology Committee to assist the Board in its oversight of
the Company&#146;s science and technology development and strategy. Dr.&nbsp;Onetto, Sam Murphy, Ph.D., and Dr.&nbsp;Rubino were appointed to the Science and Technology Committee, and Dr.&nbsp;Onetto was appointed as the Chairperson of the Science
and Technology Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;4, 2021, the Company issued a press release announcing the appointments of Dr.&nbsp;Simon and Dr.&nbsp;Rubino to the Board,
Mr.&nbsp;Chevallard&#146;s promotion to Chief Operating Officer and certain other organizational updates. A copy of the press release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under this Item&nbsp;7.01, including Exhibit 99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such
filing, unless expressly incorporated by specific reference in such filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d146113dex991.htm">Press Release, dated March&nbsp;4, 2021 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;4, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Chevallard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Chevallard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d146113dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g146113dsp5.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors and Management Team </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PR Newswire, San Diego, March</I><I></I><I>&nbsp;4, 2021 &#150; </I><U>Viracta</U> Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company
targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors, the addition of Cheryl A. Madsen, RAC as Senior Vice
President, Regulatory Affairs, and the promotion of several members of the management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The wealth of biotech leadership and executive
experience Drs. Rubino and Simon bring to the Viracta Board will be invaluable as we continue to execute on our corporate strategy,&#148; said Roger Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. &#147;With the help of
their counsel and strategic guidance, we aim to build on the momentum generated by our recent entrance into the public market and concurrent financing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased to be complementing these Board additions by bringing on Cheryl Madsen to lead our regulatory efforts,&#148; said Ivor Royston,
M.D., President and Chief Executive Officer of Viracta. &#147;Cheryl has a proven record of success facilitating the regulatory processes involved in bringing oncology therapeutics to market, which will be crucial as we advance our novel <FONT
STYLE="white-space:nowrap">all-oral</FONT> combination therapy into a global registrational trial in relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma and further expand into <FONT STYLE="white-space:nowrap">EBV-positive</FONT> solid
tumors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the appointments of Ms.&nbsp;Madsen and Drs. Rubino and Simon, Viracta also announced the following management promotions,
which are significant in the operations of Viracta as a publicly traded company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dan Chevallard, formerly Chief Financial Officer, has been promoted to Chief Operating Officer and Chief
Financial Officer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shelly Vandertie, formerly Senior Director, Finance&nbsp;&amp; Controller, has been promoted to Vice President,
Finance </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Michael Mueller, formerly Senior Director, Corporate Development&nbsp;&amp; Legal Affairs, has been promoted to
Vice President, Legal Affairs and General Counsel </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointee Bios </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stephen Rubino, Ph.D., MBA</I></B><B> </B>has over 30 years of commercial and strategic development experience in the pharmaceutical and biotechnology
industries. He is currently the Chief Business Officer at Celyad Oncology SA and sits on the Board of Sermonix Pharmaceuticals. Previously, he was the Chief Business&nbsp;&amp; Strategy Officer at Omega Therapeutics and Global Head of Business
Development and Licensing and New Product Marketing for the Cell and Gene Therapies business unit at Novartis&nbsp;Pharmaceuticals. At Novartis, Dr.&nbsp;Rubino led growth opportunities including evaluation, licensure, strategy and commercial
development of products across a wide range of therapeutic areas. He received his Ph.D. in virology from Cornell University and an MBA from Baruch College. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Barry J. Simon, M.D.,</I></B> is a healthcare executive with more than 30 years of experience spanning
the public and private sectors. He previously served on Viracta&#146;s board from July 2017 to November 2020 and is currently the President and Chief Administrative Officer (CAO) of Nantkwest, Inc. Prior to serving as Nantkwest&#146;s President and
CAO, he was the company&#146;s President and Chief Executive Officer. Dr.&nbsp;Simon also serves on the boards of several additional life science companies including Nantkwest, Cue BioPharma and Brink Biologics Inc. He has broad experience in public
and private companies, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, IND and BLA regulatory filings,
human-enabling programs, and manufacturing, quality control and life cycle management projects. Previously, he held Vice President, senior level and advisory positions at F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche, Roche Labs,
Connetics Corporation, Immunomedics, Immusol, HealthPro BioVentures, LLC, and NorthSound Capital, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In his prior roles, Dr.&nbsp;Simon worked across
several therapeutic areas including oncology, virology, ophthalmology and dermatology on product launches including Xeloda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Pegasys<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Fortovase<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Tamiflu<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&nbsp;Camptobell<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Boniva<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Fuzeon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Valcyt<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and
Accutane<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Dr.&nbsp;Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He received his M.D. from the SUNY
Downstate Health&nbsp;Sciences Center in New York and trained clinically in infectious diseases, anesthesiology, and internal medicine at Albert Einstein College of Medicine, The Mount Sinai Medical Center and New York University, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cheryl A. Madsen, RAC</I></B> brings over 25 years of regulatory affairs experience in the development of both biologics and small molecules ranging
from <FONT STYLE="white-space:nowrap">pre-IND</FONT> through commercial stage companies. Ms.&nbsp;Madsen joined Viracta Therapeutics from Calithera Biosciences where she served as Vice President of Regulatory Affairs.&nbsp;Previously,
Ms.&nbsp;Madsen was the Vice President of Regulatory Affairs at Peloton Therapeutics where she facilitated the successful acquisition of their HIF2-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor (belzutifan) by Merck.&nbsp;Prior to that,
she was a Senior Director at Medivation (acquired by Pfizer), where she played an instrumental role in the initial global regulatory filings, approval and launch of XTANDI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(enzalutamide)
for the treatment of metastatic castration-resistant prostate cancer.&nbsp;In addition to her regulatory responsibilities, she served as Project Team Leader for XTANDI from 2015-2016.&nbsp;She started her career at Genentech, where during her <FONT
STYLE="white-space:nowrap">13-year</FONT> tenure she was responsible for the original filing and approval of AVASTIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(bevacizumab) for first-line metastatic colorectal cancer.&nbsp;She
also played a critical role in the parallel filing and approval of the HERCEPTIN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(trastuzumab) BLA for metastatic breast cancer and the premarket approval of HercepTest<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, an<I>&nbsp;in vitro</I>&nbsp;diagnostic for HER2 expression and patient selection. Ms.&nbsp;Madsen received her bachelors degree in Psychology from U.C. Santa Cruz and completed additional
post-graduate work in Molecular Biology and Biochemistry at U.C. Berkeley.&nbsp;She also holds U.S. and Global Regulatory Affairs Certifications from the Regulatory Affairs Professional Society. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Viracta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta&#146;s proprietary investigational drug, nanatinostat, is currently
being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">EBV-positive</FONT> lymphoma. Viracta is pursuing application of this inducible
synthetic lethality approach in other <FONT STYLE="white-space:nowrap">EBV-associated</FONT> malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information please visit&nbsp;<U>www.viracta.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains
&#147;forward-looking&#148; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the significance of the Board of Director and management appointments and the
expected contribution of the appointees; Viracta&#146;s clinical development plans; and other statements that are not historical facts.&nbsp;Risks and uncertainties related to Viracta that may cause actual results to differ materially from those
expressed or implied in any forward-looking statement include, but are not limited to: Viracta&#146;s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta&#146;s plans to develop and commercialize
its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta&#146;s planned clinical trials; the timing of the availability of data from Viracta&#146;s clinical trials; previous
preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta&#146;s plans to research, develop and commercialize its current and
future product candidates; the clinical utility, potential benefits and market acceptance of Viracta&#146;s product candidates; Viracta&#146;s ability to identify additional products or product candidates with significant commercial potential;
developments and projections relating to Viracta&#146;s competitors and its industry; the impact of government laws and regulations; Viracta&#146;s ability to protect its intellectual property position; and Viracta&#146;s estimates regarding future
expenses, capital requirements and need for additional financing in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks and uncertainties may be amplified by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by
these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#147;Risk Factors&#148;
and elsewhere in Viracta&#146;s reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at&nbsp;<U>www.sec.gov</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update
these forward-looking statements, except as required by law or applicable regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Relations Contact:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Company Contact:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joyce Allaire</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dan Chevallard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LifeSci Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>jallaire@lifesciadvisors.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>dchevallard@viracta.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">915-2569</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(858) <FONT STYLE="white-space:nowrap">771-4193</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SOURCE Viracta Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g146113dsp5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g146113dsp5.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\?>RO_UZUQ=51CR6W,,!0<Y>TOL5?%7B/4_&WB0:3IN_[+YACAB0\28_B/\
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2 !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
